ID   PCSK9_RAT               Reviewed;         691 AA.
AC   P59996; Q5I6U6;
DT   07-NOV-2003, integrated into UniProtKB/Swiss-Prot.
DT   07-NOV-2003, sequence version 1.
DT   24-JUL-2024, entry version 150.
DE   RecName: Full=Proprotein convertase subtilisin/kexin type 9;
DE            EC=3.4.21.-;
DE   AltName: Full=Neural apoptosis-regulated convertase 1;
DE            Short=NARC-1;
DE   AltName: Full=Proprotein convertase 9;
DE            Short=PC9;
DE   AltName: Full=Subtilisin/kexin-like protease PC9;
DE   Flags: Precursor;
GN   Name=Pcsk9; Synonyms=Narc1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE.
RA   Chiang L.W.;
RT   "Narc-1, novel subtilase-like homologs.";
RL   Patent number WO0157081, 09-AUG-2001.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Liver;
RA   Petkov P., Grozdanov P., Hadjiolova K., Karagyozov L., Dabeva M.;
RT   "Rat proprotein convertase subtilisin/kexin type 9.";
RL   Submitted (DEC-2004) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Liver;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   CHARACTERIZATION.
RX   PubMed=12552133; DOI=10.1073/pnas.0335507100;
RA   Seidah N.G., Benjannet S., Wickham L., Marcinkiewicz J., Jasmin S.B.,
RA   Stifani S., Basak A., Prat A., Chretien M.;
RT   "The secretory proprotein convertase neural apoptosis-regulated convertase
RT   1 (NARC-1): liver regeneration and neuronal differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:928-933(2003).
RN   [5]
RP   CHARACTERIZATION, AUTOCATALYTIC CLEAVAGE SITE, AND MUTAGENESIS OF GLN-151;
RP   SER-152; HIS-225 AND SER-385.
RX   PubMed=14622975; DOI=10.1016/j.abb.2003.09.011;
RA   Naureckiene S., Ma L., Sreekumar K., Purandare U., Lo C.F., Huang Y.,
RA   Chiang L.W., Grenier J.M., Ozenberger B.A., Jacobsen J.S., Kennedy J.D.,
RA   DiStefano P.S., Wood A., Bingham B.;
RT   "Functional characterization of Narc 1, a novel proteinase related to
RT   proteinase K.";
RL   Arch. Biochem. Biophys. 420:55-67(2003).
CC   -!- FUNCTION: Crucial player in the regulation of plasma cholesterol
CC       homeostasis. Binds to low-density lipid receptor family members: low
CC       density lipoprotein receptor (LDLR), very low density lipoprotein
CC       receptor (VLDLR), apolipoprotein E receptor (LRP1/APOER) and
CC       apolipoprotein receptor 2 (LRP8/APOER2), and promotes their degradation
CC       in intracellular acidic compartments. Acts via a non-proteolytic
CC       mechanism to enhance the degradation of the hepatic LDLR through a
CC       clathrin LDLRAP1/ARH-mediated pathway. May prevent the recycling of
CC       LDLR from endosomes to the cell surface or direct it to lysosomes for
CC       degradation. Can induce ubiquitination of LDLR leading to its
CC       subsequent degradation. Inhibits intracellular degradation of APOB via
CC       the autophagosome/lysosome pathway in a LDLR-independent manner.
CC       Involved in the disposal of non-acetylated intermediates of BACE1 in
CC       the early secretory pathway. Inhibits epithelial Na(+) channel (ENaC)-
CC       mediated Na(+) absorption by reducing ENaC surface expression primarily
CC       by increasing its proteasomal degradation. Regulates neuronal apoptosis
CC       via modulation of LRP8/APOER2 levels and related anti-apoptotic
CC       signaling pathways (By similarity). {ECO:0000250}.
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Its proteolytic activity is autoinhibited by the
CC       non-covalent binding of the propeptide to the catalytic domain.
CC       Inhibited by EGTA (By similarity). {ECO:0000250}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 8-11.;
CC       Temperature dependence:
CC         Optimum temperature is 37 degrees Celsius.;
CC   -!- SUBUNIT: Monomer. Can self-associate to form dimers and higher
CC       multimers which may have increased LDLR degrading activity. The
CC       precursor protein but not the mature protein may form multimers.
CC       Interacts with APOB, VLDLR, LRP8/APOER2 and BACE1. The full-length
CC       immature form (pro-PCSK9) interacts with SCNN1A, SCNN1B and SCNN1G. The
CC       pro-PCSK9 form (via C-terminal domain) interacts with LDLR. Interacts
CC       (via the C-terminal domain) with ANXA2 (via repeat Annexin 1); the
CC       interaction inhibits the degradation of LDLR.
CC       {ECO:0000250|UniProtKB:Q8NBP7}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Secreted {ECO:0000250}.
CC       Endosome {ECO:0000250}. Lysosome {ECO:0000250}. Cell surface
CC       {ECO:0000250}. Endoplasmic reticulum {ECO:0000250}. Golgi apparatus
CC       {ECO:0000250}. Note=Autocatalytic cleavage is required to transport it
CC       from the endoplasmic reticulum to the Golgi apparatus and for the
CC       secretion of the mature protein. Localizes to the endoplasmic reticulum
CC       in the absence of LDLR and colocalizes to the cell surface and to the
CC       endosomes/lysosomes in the presence of LDLR. The sorting to the cell
CC       surface and endosomes is required in order to fully promote LDLR
CC       degradation (By similarity). {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highly expressed in 12-day embryo. In the adult,
CC       strongly expressed in liver, small intestine, jejunum, and to a lesser
CC       extent in kidney, lung, spleen and thymus. Expression in the liver is
CC       up-regulated following partial hepatectomy.
CC   -!- DOMAIN: The C-terminal domain (CRD) is essential for the LDLR-binding
CC       and degrading activities. {ECO:0000250}.
CC   -!- DOMAIN: The catalytic domain is responsible for mediating its self-
CC       association. {ECO:0000250}.
CC   -!- PTM: Cleavage by furin and PCSK5 generates a truncated inactive protein
CC       that is unable to induce LDLR degradation. {ECO:0000250}.
CC   -!- PTM: Undergoes autocatalytic cleavage in the endoplasmic reticulum to
CC       release the propeptide from the N-terminus and the cleavage of the
CC       propeptide is strictly required for its maturation and activation. The
CC       cleaved propeptide however remains associated with the catalytic domain
CC       through non-covalent interactions, preventing potential substrates from
CC       accessing its active site. As a result, it is secreted from cells as a
CC       propeptide-containing, enzymatically inactive protein (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation protects the propeptide against proteolysis.
CC       {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the peptidase S8 family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAC60363.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AX207690; CAC60363.1; ALT_INIT; Unassigned_DNA.
DR   EMBL; AY847775; AAW31850.1; -; mRNA.
DR   EMBL; BC133063; AAI33064.1; -; mRNA.
DR   RefSeq; NP_954862.2; NM_199253.2.
DR   AlphaFoldDB; P59996; -.
DR   SMR; P59996; -.
DR   STRING; 10116.ENSRNOP00000008536; -.
DR   MEROPS; S08.039; -.
DR   GlyCosmos; P59996; 1 site, No reported glycans.
DR   GlyGen; P59996; 1 site.
DR   iPTMnet; P59996; -.
DR   PhosphoSitePlus; P59996; -.
DR   PaxDb; 10116-ENSRNOP00000008536; -.
DR   ABCD; P59996; 2 sequenced antibodies.
DR   Ensembl; ENSRNOT00000008535.6; ENSRNOP00000008536.5; ENSRNOG00000006280.6.
DR   Ensembl; ENSRNOT00055055053; ENSRNOP00055045498; ENSRNOG00055031814.
DR   Ensembl; ENSRNOT00060034363; ENSRNOP00060028195; ENSRNOG00060019885.
DR   Ensembl; ENSRNOT00065038186; ENSRNOP00065030917; ENSRNOG00065022391.
DR   GeneID; 298296; -.
DR   KEGG; rno:298296; -.
DR   UCSC; RGD:728909; rat.
DR   AGR; RGD:728909; -.
DR   CTD; 255738; -.
DR   RGD; 728909; Pcsk9.
DR   eggNOG; KOG1153; Eukaryota.
DR   GeneTree; ENSGT00490000043472; -.
DR   HOGENOM; CLU_011263_11_0_1; -.
DR   InParanoid; P59996; -.
DR   OMA; GEEMMGC; -.
DR   OrthoDB; 380531at2759; -.
DR   PhylomeDB; P59996; -.
DR   TreeFam; TF106271; -.
DR   Reactome; R-RNO-381426; Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs).
DR   Reactome; R-RNO-8866427; VLDLR internalisation and degradation.
DR   Reactome; R-RNO-8957275; Post-translational protein phosphorylation.
DR   Reactome; R-RNO-8964038; LDL clearance.
DR   PRO; PR:P59996; -.
DR   Proteomes; UP000002494; Chromosome 5.
DR   Bgee; ENSRNOG00000006280; Expressed in liver and 6 other cell types or tissues.
DR   GO; GO:0009986; C:cell surface; ISS:UniProtKB.
DR   GO; GO:0030134; C:COPII-coated ER to Golgi transport vesicle; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005769; C:early endosome; ISS:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; ISS:UniProtKB.
DR   GO; GO:0005576; C:extracellular region; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IDA:RGD.
DR   GO; GO:0005794; C:Golgi apparatus; ISS:UniProtKB.
DR   GO; GO:0005770; C:late endosome; ISS:UniProtKB.
DR   GO; GO:0005764; C:lysosome; ISS:UniProtKB.
DR   GO; GO:1990667; C:PCSK9-AnxA2 complex; ISO:RGD.
DR   GO; GO:1990666; C:PCSK9-LDLR complex; ISO:RGD.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0034185; F:apolipoprotein binding; ISS:UniProtKB.
DR   GO; GO:0034190; F:apolipoprotein receptor binding; ISO:RGD.
DR   GO; GO:0030169; F:low-density lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0050750; F:low-density lipoprotein particle receptor binding; ISS:HGNC-UCL.
DR   GO; GO:0004252; F:serine-type endopeptidase activity; ISS:HGNC-UCL.
DR   GO; GO:0030547; F:signaling receptor inhibitor activity; ISO:RGD.
DR   GO; GO:0019871; F:sodium channel inhibitor activity; ISO:RGD.
DR   GO; GO:0034189; F:very-low-density lipoprotein particle binding; ISS:UniProtKB.
DR   GO; GO:0070326; F:very-low-density lipoprotein particle receptor binding; ISO:RGD.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0032869; P:cellular response to insulin stimulus; IDA:HGNC-UCL.
DR   GO; GO:0009267; P:cellular response to starvation; IDA:HGNC-UCL.
DR   GO; GO:0042632; P:cholesterol homeostasis; IEP:RGD.
DR   GO; GO:0008203; P:cholesterol metabolic process; ISO:RGD.
DR   GO; GO:0001822; P:kidney development; IEP:HGNC-UCL.
DR   GO; GO:0042157; P:lipoprotein metabolic process; ISO:RGD.
DR   GO; GO:0001889; P:liver development; IEP:HGNC-UCL.
DR   GO; GO:0032802; P:low-density lipoprotein particle receptor catabolic process; ISS:UniProtKB.
DR   GO; GO:0032799; P:low-density lipoprotein receptor particle metabolic process; ISO:RGD.
DR   GO; GO:0007041; P:lysosomal transport; ISO:RGD.
DR   GO; GO:0010989; P:negative regulation of low-density lipoprotein particle clearance; ISO:RGD.
DR   GO; GO:0002091; P:negative regulation of receptor internalization; ISO:RGD.
DR   GO; GO:0001920; P:negative regulation of receptor recycling; ISO:RGD.
DR   GO; GO:1905601; P:negative regulation of receptor-mediated endocytosis involved in cholesterol transport; ISO:RGD.
DR   GO; GO:0022008; P:neurogenesis; IEP:HGNC-UCL.
DR   GO; GO:0030182; P:neuron differentiation; ISS:HGNC-UCL.
DR   GO; GO:0006644; P:phospholipid metabolic process; ISO:RGD.
DR   GO; GO:0032805; P:positive regulation of low-density lipoprotein particle receptor catabolic process; ISO:RGD.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IDA:HGNC-UCL.
DR   GO; GO:0002092; P:positive regulation of receptor internalization; ISO:RGD.
DR   GO; GO:0016540; P:protein autoprocessing; IDA:RGD.
DR   GO; GO:0016485; P:protein processing; IDA:RGD.
DR   GO; GO:0032803; P:regulation of low-density lipoprotein particle receptor catabolic process; ISO:RGD.
DR   GO; GO:0043523; P:regulation of neuron apoptotic process; ISS:UniProtKB.
DR   GO; GO:0006641; P:triglyceride metabolic process; ISO:RGD.
DR   CDD; cd04077; Peptidases_S8_PCSK9_ProteinaseK_like; 1.
DR   Gene3D; 3.30.70.80; Peptidase S8 propeptide/proteinase inhibitor I9; 1.
DR   Gene3D; 3.40.50.200; Peptidase S8/S53 domain; 1.
DR   Gene3D; 2.60.120.690; Proprotein convertase subtilisin/kexin type 9; 1.
DR   InterPro; IPR041254; PCSK9_C1.
DR   InterPro; IPR041052; PCSK9_C2.
DR   InterPro; IPR041051; PCSK9_C3.
DR   InterPro; IPR034193; PCSK9_ProteinaseK-like.
DR   InterPro; IPR000209; Peptidase_S8/S53_dom.
DR   InterPro; IPR036852; Peptidase_S8/S53_dom_sf.
DR   InterPro; IPR050131; Peptidase_S8_subtilisin-like.
DR   InterPro; IPR015500; Peptidase_S8_subtilisin-rel.
DR   InterPro; IPR010259; S8pro/Inhibitor_I9.
DR   InterPro; IPR037045; S8pro/Inhibitor_I9_sf.
DR   PANTHER; PTHR43806; PEPTIDASE S8; 1.
DR   PANTHER; PTHR43806:SF60; PROPROTEIN CONVERTASE SUBTILISIN_KEXIN TYPE 9; 1.
DR   Pfam; PF05922; Inhibitor_I9; 1.
DR   Pfam; PF18459; PCSK9_C1; 1.
DR   Pfam; PF18464; PCSK9_C2; 1.
DR   Pfam; PF18463; PCSK9_C3; 1.
DR   Pfam; PF00082; Peptidase_S8; 1.
DR   PRINTS; PR00723; SUBTILISIN.
DR   SUPFAM; SSF54897; Protease propeptides/inhibitors; 1.
DR   SUPFAM; SSF52743; Subtilisin-like; 1.
DR   PROSITE; PS51892; SUBTILASE; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; Autocatalytic cleavage; Calcium; Cholesterol metabolism;
KW   Cytoplasm; Disulfide bond; Endoplasmic reticulum; Endosome; Glycoprotein;
KW   Golgi apparatus; Hydrolase; Lipid metabolism; Lysosome; Phosphoprotein;
KW   Protease; Reference proteome; Secreted; Serine protease; Signal;
KW   Steroid metabolism; Sterol metabolism; Sulfation; Zymogen.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000255"
FT   PROPEP          31..151
FT                   /id="PRO_0000027124"
FT   CHAIN           152..691
FT                   /note="Proprotein convertase subtilisin/kexin type 9"
FT                   /id="PRO_0000027125"
FT   DOMAIN          154..441
FT                   /note="Peptidase S8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   REGION          449..691
FT                   /note="C-terminal domain"
FT                   /evidence="ECO:0000250"
FT   MOTIF           495..497
FT                   /note="Cell attachment site"
FT                   /evidence="ECO:0000255"
FT   ACT_SITE        185
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   ACT_SITE        225
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   ACT_SITE        385
FT                   /note="Charge relay system"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU01240"
FT   SITE            151..152
FT                   /note="Cleavage; by autolysis"
FT   SITE            217..218
FT                   /note="Cleavage; by furin and PCSK5"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         37
FT                   /note="Sulfotyrosine"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         46
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8NBP7"
FT   MOD_RES         687
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8NBP7"
FT   CARBOHYD        532
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000250"
FT   DISULFID        222..254
FT                   /evidence="ECO:0000255"
FT   DISULFID        322..357
FT                   /evidence="ECO:0000255"
FT   DISULFID        456..526
FT                   /evidence="ECO:0000255"
FT   DISULFID        476..525
FT                   /evidence="ECO:0000255"
FT   DISULFID        485..508
FT                   /evidence="ECO:0000255"
FT   DISULFID        533..600
FT                   /evidence="ECO:0000255"
FT   DISULFID        551..599
FT                   /evidence="ECO:0000255"
FT   DISULFID        561..587
FT                   /evidence="ECO:0000255"
FT   DISULFID        607..678
FT                   /evidence="ECO:0000255"
FT   DISULFID        625..677
FT                   /evidence="ECO:0000255"
FT   DISULFID        634..653
FT                   /evidence="ECO:0000255"
FT   MUTAGEN         151
FT                   /note="Q->E,N: No effect; when associated with A-152."
FT                   /evidence="ECO:0000269|PubMed:14622975"
FT   MUTAGEN         151
FT                   /note="Q->I: Abolishes autocleavage; when associated with
FT                   V-152."
FT                   /evidence="ECO:0000269|PubMed:14622975"
FT   MUTAGEN         152
FT                   /note="S->A: No effect; when associated with E-151 or N-
FT                   151."
FT                   /evidence="ECO:0000269|PubMed:14622975"
FT   MUTAGEN         152
FT                   /note="S->V: Abolishes autocleavage; when associated with
FT                   I-151."
FT                   /evidence="ECO:0000269|PubMed:14622975"
FT   MUTAGEN         225
FT                   /note="H->W: Abolishes autocleavage."
FT                   /evidence="ECO:0000269|PubMed:14622975"
FT   MUTAGEN         385
FT                   /note="S->A: Abolishes autocleavage."
FT                   /evidence="ECO:0000269|PubMed:14622975"
SQ   SEQUENCE   691 AA;  74709 MW;  8084A880CCAE5BA6 CRC64;
     MGIRCSTWLR WPLSPQLLLL LLLCPTGSRA QDEDGDYEEL MLALPSQEDS LVDEASHVAT
     ATFRRCSKEA WRLPGTYVVV LMEETQRLQV EQTAHRLQTW AARRGYVIKV LHVFYDLFPG
     FLVKMSSDLL GLALKLPHVE YIEEDSLVFA QSIPWNLERI IPAWQQTEED SSPDGSSQVE
     VYLLDTSIQS GHREIEGRVT ITDFNSVPEE DGTRFHRQAS KCDSHGTHLA GVVSGRDAGV
     AKGTSLHSLR VLNCQGKGTV SGTLIGLEFI RKSQLIQPSG PLVVLLPLAG GYSRILNTAC
     QRLARTGVVL VAAAGNFRDD ACLYSPASAP EVITVGATNA QDQPVTLGTL GTNFGRCVDL
     FAPGKDIIGA SSDCSTCYMS QSGTSQAAAH VAGIVAMMLN RDPALTLAEL RQRLILFSTK
     DVINMAWFPE DQRVLTPNRV ATLPPSTQET GGQLLCRTVW SAHSGPTRTA TATARCAPEE
     ELLSCSSFSR SGRRRGDRIE AIGGQQVCKA LNAFGGEGVY AVARCCLLPR VNCSIHNTPA
     ARAGPQTPVH CHQKDHVLTG CSFHWEVENL RAQQQPLLRS RHQPGQCVGH QEASVHASCC
     HAPGLECKIK EHGIAGPAEQ VTVACEAGWT LTGCNVLPGA SLPLGAYSVD NVCVARIRDA
     GRADRTSEEA TVAAAICCRS RPSAKASWVH Q
//
